RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

Biogen187 enrolled

Overview

Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis. Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy. This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

187

Conditions

Breast Cancer

Interventions

Omaveloxolone Lotion 0.5%DRUG

Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

Omaveloxolone Lotion 3%DRUG

Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

Vehicle LotionDRUG

Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

3D conformal radiation therapyRADIATION

45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult female patients (18 to 75 years of age, inclusive); 2. Patients diagnosed with ductal carcinoma in situ or non-inflammatory breast adenocarcinoma who have been referred for post-operative radiotherapy and have had no prior radiation treatment to that breast; 3. Patients planning to undergo 3D conformal radiation therapy to the whole breast (as part of breast-conservation therapy / lumpectomy) or chest wall (as part of post-mastectomy irradiation), with or without treatment of regional lymph nodes (i.e., axillary, supraclavicular, or internal mammary), using one of the following treatment schedules: 1. 45 - 50.4 Gy in 1.8 Gy per day, in addition to 10-16 Gy boost 2. 46 - 50 Gy in 2 Gy per day, in addition to 10-16 Gy boost; 4. Patients who received breast-conservation therapy / lumpectomy must be receiving ≥ 107% of the total radiation dose (calculated from the total radiation dose including boost) to any portion of the breast, based on radiation inhomogeneity, and/or have a breast volume ≥ 1200 cc; Exclusion Criteria: 1. Patients with Stage T4 or Stage IV breast cancer; 2. Patients with prior radiation therapy to the breast treated in this study; 3. Patients with type V or VI skin according to the Fitzpatrick scale; 4. Patients with bilateral breast cancer; 5. Patients receiving partial breast irradiation therapy; 6. Patients with uncontrolled diabetes (HbA1c \> 11.0%, historical values within 6 months of screening are acceptable); 7. Patients with collagen vascular disease or vasculitis; 8. Patients with concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix; 9. Patients with active bacterial, fungal or viral skin infections; 10. Patients with known active hepatitis B or hepatitis C infection; 11. Patients who intend to use any other topical cream, lotion or preparation applied to the radiation treatment area; 12. Patients receiving concomitant chemotherapy during the course of the planned radiation treatment regimen. Patients are eligible if they are receiving sequential, neoadjuvant or adjuvant chemotherapy that is not anticipated to be delivered during the time course of the radiation treatment regimen.

Locations (27)

Ironwood Cancer and Research Centers

Mesa, Arizona, United States

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Arizona Cancer Center

Scottsdale, Arizona, United States

University of Colorado Hospital, Dept. of Radiation Oncology

Aurora, Colorado, United States

Norwalk Hospital

Norwalk, Connecticut, United States

Outcomes

Primary Outcomes

Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle

CTCAE Radiation dermatitis scoring: Grade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death

Time frame: Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported